Skip to main content
OpenTrials
Completed

NCT Number: NCT00742885

Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine

This trial will assess the immunogenicity and safety elicited by the adjuvanted GSK Biologicals' (pre-) pandemic influenza candidate vaccine in healthy Japanese adults.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Influenza Infections Influenza, Human Orthomyxoviridae Infections RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

20 year–64 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

GSK Investigational Site, Fukuoka, Japan

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Japanese male and female adults 20 to 64 years of age at time of the first vaccination, inclusive.
  • Good general health as assessed by medical history and physical examination.
  • Access to a consistent means of telephone contact, which may be either in the home or at the workplace, land line or mobile, but NOT a pay phone or other multiple-user device.
  • Written informed consent obtained from the subject.
  • Comprehension of the study requirements, expressed availability for the required study period, and ability to attend scheduled visits.
  • Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study.

Exclusion criteria

  • Presence of significant acute or chronic, uncontrolled medical or psychiatric illness.
  • Presence or evidence of substance abuse or of neurological or psychiatric diagnoses which, although stable, are deemed by the investigator to render the potential subject unable/unlikely to provide accurate safety reports.
  • Diagnosed with cancer, or treatment for cancer within 3 years.
  • Presence of an axillary temperature >= 37.5 °C, or acute symptoms greater than "mild" severity on the scheduled date of first vaccination.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition including history of human immunodeficiency virus (HIV) infection.
  • Receipt of systemic glucocorticoids within 1 month of study enrolment, or any other cytotoxic or immunosuppressive drug within 6 months of study enrolment.
  • Any significant disorder of coagulation or treatment with Coumadin derivatives or heparin.
  • Administration of any registered vaccine within 30 days before study enrolment or planned administration within the first vaccination up to blood sampling at Day 42 and within 30 days prior to blood sampling at Day 182.
  • Use of any investigational or non-registered product within 30 days prior to study enrolment or planned use during the study period.
  • History of previous H5N1 vaccination, or history of H5N1 influenza infection.
  • Receipt of any immunoglobulins and/or any blood products within 6 months of study enrolment or planned administration of any of these products during the study period.
  • Any known or suspected allergy to any constituent of influenza vaccines or component used in the manufacturing process of the study vaccine, a history of anaphylactic-type reaction to consumption of eggs; or a history of severe adverse reaction to a previous influenza vaccine.
  • Known pregnancy or a positive urine beta-human chorionic gonadotropin test result prior to the time of first vaccination.
  • Lactating or nursing.
  • Women of child-bearing potential who lack a history of reliable contraceptive practices. The provision of this history does NOT replace the requirement to perform, and obtain negative results in pregnancy urine tests prior to treatments; all women will have urine pregnancy tests regardless of their status.
  • Known receipt of analgesic or antipyretic medication on the day of treatment (Day 0).

Treatment and study plan

Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted

Biological

All subjects will receive 2 doses administered as an intramuscular (IM) injection.

Other names: PumarixTM

Primary outcomes

  1. Haemagglutination Inhibition (HI) Antibody Titers for the H5N1 Vaccine Strain

    Time frame: At Day 0 and Day 42

    Antibody titers were expressed as Geometric mean titers (GMTs). The H5N1 vaccine strain included A/Indonesia/05/2005 antigen (A/Indonesia).

  2. Number of Subjects Seroconverted for H5N1 HI Antibodies

    Time frame: At Day 42

    A seroconverted subject was defined as a subject who had either a pre-vaccination titer below 1:10 and a post-vaccination titer greater than or equal to 1:40 or a pre-vaccination titer greater than or equal to 1:10 and at least a 4-fold increase in post-vaccination titer. The H5N1 vaccine strain included A/Indonesia antigen.

  3. HI Antibody Seroconversion Factors for H5N1 HI Antibodies

    Time frame: At Day 0 and Day 42

    Seroconversion factors (SCF) were defined as the fold increase in serum H5N1 HI antibody GMTs post-vaccination compared to Day 0, at Day 42. The H5N1 vaccine strain included A/Indonesia antigen.

  4. Number of Subjects Seroprotected for H5N1 HI Antibodies

    Time frame: At Day 42

    A seroprotected subject was defined as a subject with a serum H5N1 HI antibody titer greater than or equal to 1:40, at Day 42. The H5N1 vaccine strain included A/Indonesia antigen.

  5. Haemagglutination Inhibition (HI) Antibody Titers for the H5N1 Vaccine Strain

    Time frame: At Day 0, Day 21 and Day 182

    Antibody titers were expressed as Geometric mean titers (GMTs). The H5N1 vaccine strain included A/Indonesia antigen.

Secondary outcomes

  1. Number of Subjects Seroconverted for H5N1 HI Antibodies

    Time frame: At Day 21 and Day 182

    A seroconverted subject was defined as a subject who had either a pre-vaccination titer below 1:10 and a post-vaccination titer greater than or equal to 1:40 or a pre-vaccination titer greater than or equal to 1:10 and at least a 4-fold increase in post-vaccination titer, at Days 21 and 182. The H5N1 vaccine strain included A/Indonesia antigen.

  2. Seroconversion Factors for H5N1 HI Antibodies

    Time frame: At Day 21 and Day 182

    Seroconversion factors (SCF) were defined as the fold increase in serum H5N1 HI antibody GMTs post-vaccination compared to Day 0, at Days 21 and 182. The H5N1 vaccine strain included A/Indonesia antigen.

  3. Number of Subjects Seroprotected for H5N1 HI Antibodies

    Time frame: At Day 0, Day 21 and Day 182

    A seroprotected subject was defined as a subject with a serum H5N1 HI antibody titer greater than or equal to 1:40, at Days 21 and 182. The H5N1 vaccine strain included A/Indonesia antigen.

  4. Antibody Titers for Serum Anti-H5N1 Neutralising Antibodies

    Time frame: At Day 0, Day 42 and Day 182

    Antibody titers were expressed as Geometric mean titers (GMTs). The H5N1 vaccine strain included A/Indonesia antigen.

  5. Number of Subjects Seroconverted for Serum Anti-H5N1 Neutralising Antibodies

    Time frame: At Day 42 and Day 182

    A seroconverted subject was defined as a subject with a minimum 4 fold increase in titer at post-vaccination for neutralising antibody response at Days 42 and 182.

    The H5N1 vaccine strain included A/Indonesia antigen.

  6. Number of Subjects With Any Biochemical and Haematological Laboratory Abnormalities

    Time frame: At Day 0, Day 7 and Day 42

    Biochemical and haematological parameters assessed in blood samples include alanine aminotransferase (ALT), aspartate aminotransferase (AST), basophils (BAS) and blood urea nitrogen (BUN ). Categories = unknown, below, within, or above the normal ranges.

  7. Number of Subjects With Any Biochemical and Haematological Laboratory Abnormalities

    Time frame: At Day 0, Day 7 and Day 42

    Biochemical and haematological parameters assessed in blood samples include creatinine (CREA), eosinophils (EOS), hemoglobin (HB) and hematocrit (HC).

    Categories = unknown, below, within, or above the normal ranges.

  8. Number of Subjects With Any Biochemical and Haematological Laboratory Abnormalities

    Time frame: At Day 0, Day 7 and Day 42

    Biochemical and haematological parameters assessed in blood samples include lymphocytes (LYM), monocytes (MON) and neutrophils (NEU).

    Categories = unknown, below, within, or above the normal ranges.

  9. Number of Subjects With Any Normal or Abnormal Urine Values

    Time frame: At Day 0, Day 7 and Day 42

    Urine parameters assessed were blood, glucose, protein and urobilinogen. Categories = negative, positive

  10. Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms

    Time frame: During the 7-day post vaccination period (Days 0-6) after any vaccination

    Solicited local symptoms assessed were pain, redness and swelling/induration. Any=any solicited local symptom reported regardless of their intensity. Grade 3 pain= significant pain at rest that prevented normal activities as assessed by inability to attend/do work or school. Grade 3 redness and swelling/induration=redness and swelling/induration above 100 millimetres (mm).

  11. Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms

    Time frame: During the 7-day post vaccination period (Days 0-6) after any vaccination

    Solicited general symptoms assessed were fatigue, headache, joint pain, muscle aches, shivering, increase sweating and fever. Any=any solicited general symptom reported regardless of their intensity grade or their relationship to vaccination. Any fever was ≥ 38.0 degrees celsius (°C). Grade 3 = general symptom that prevented normal everyday activities as assessed by inability to attend/do work or school, or required intervention of a physician/healthcare provider. Grade 3 fever was≥ 39.0°C. Related= general symptom assessed by the investigator as causally related to the study vaccination.

  12. Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Adverse Events (AEs)

    Time frame: During the 21-day (Days 0-20) following vaccination

    Unsolicited AE is any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 was an event that prevented normal activities and related was defined as an unsolicited AE assessed by the investigator to be causally related to the study vaccination.

  13. Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs

    Time frame: From Day 0 to Day 83 following vaccination

    Unsolicited AE is any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 was an event that prevented normal activities and related was defined as an unsolicited AE assessed by the investigator to be causally related to the study vaccination.

  14. Number of Subjects Reporting Any Medically-significant Conditions (MSCs)

    Time frame: During the 182-day (Days 0-181) post-vaccination period

    MSCs were defined as AEs with a medically-attended visit (s) i.e. prompting emergency room (ER) visits, hospitalizations or physician visits and that were not routine visits for physical examination or vaccination.

  15. Number of Subjects Reporting Serious Adverse Events (SAEs)

    Time frame: During the entire study period (Day 0 to Day 181)

    SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.

Sponsors and collaborators

Lead sponsor

GlaxoSmithKline

Industry

Registry information

Official study title

Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine GSK 1557484A.

Important dates

Study start
2008
Primary completion
2009
Study completion
2009
First posted
Aug 28, 2008
Registry last updated
Aug 20, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.